MULTICENTER STUDY
Add like
Add dislike
Add to saved papers

Reperfusion Rates of Pulmonary Arteriovenous Malformations after Coil Embolization: Evaluation with Time-Resolved MR Angiography or Pulmonary Angiography.

PURPOSE: To assess reperfusion rates after coil embolization for pulmonary arteriovenous malformations (PAVMs) using time-resolved magnetic resonance (MR) angiography or pulmonary angiography.

MATERIALS AND METHODS: Patients with PAVMs who underwent embolization and met the following inclusion criteria were included: (a) embolization was performed using bare or fibered platinum microcoils or both, (b) the complete cessation of flow was confirmed by digital subtraction angiography, and (c) follow-up examinations were conducted with time-resolved MR angiography or pulmonary angiography. Coil embolization was performed in 16 patients with 24 untreated or reperfused PAVMs. Sac embolization was performed for 12 untreated PAVMs. Feeding artery embolization was performed as primary embolization in each of the 12 reperfused PAVMs. Five PAVMs were treated 2 to 4 times because of reperfusion. The study included 32 coil embolizations. Follow-up images were reviewed, and reperfusion rates were assessed. The relationships between reperfusion and the location of PAVM, size of PAVM (feeding artery and venous sac), coils (number and total length), timing of embolization (primary or repeat embolization), and types of coils used (with or without fibered coils) were examined.

RESULTS: Reperfusion rates at 3, 6, 12, and 24 months were 8%, 27%, 36%, and 49%, respectively, for the 12 untreated PAVMs (primary embolization) and 50%, 50%, 92%, and 100%, respectively, for the 12 reperfused PAVMs (repeat embolization) (P = .0062). No significant differences were observed in the other parameters measured.

CONCLUSIONS: When evaluated with time-resolved MR angiography or pulmonary angiography, reperfusion rates after coil embolization for PAVM were considerably high, particularly with repeat embolization.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app